Clinical trialNCT03428802Active, not recruitingPhase 2Interventional

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

SponsorRutgers, The State University of New JerseyEnrollment21BRCA1 Gene MutationBRCA2 Gene MutationLocally Advanced Solid NeoplasmMetastatic Malignant Solid NeoplasmPOLD1 Gene MutationPOLE Gene Mutation+14 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial studies how well pembrolizumab works in treating participants with cancer that has spread to other places in the body, has come back or has spread to nearby tissues or lymph nodes. Monoclonal antibodies such as, pembrolizumab, may interfere with the ability of tumor cells to grow and spread.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Eugenia Girda, MD
Rutgers Cancer Institute of New Jersey
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Laura & Isaac Perlmutter Cancer Center at Nyu Langone Health
New York, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Pembrolizumab

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 8 Mar 2018
Primary completion: 24 Nov 2024
Completion: 21 Sept 2027
Last update posted: 3 Apr 2026
Registered enrollment: 21
Registry id: NCT03428802

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.